NU-RANIT TAB 150MG 150 MG
RANITIDINE (RANITIDINE HYDROCHLORIDE) : 150 MG · DIN 00865737 · NU-PHARM INC
Health Canada status: CANCELLED POST MARKET
What is NU-RANIT TAB 150MG?
NU-RANIT TAB 150MG 150 MG contains RANITIDINE (RANITIDINE HYDROCHLORIDE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 00865737, held by NU-PHARM INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 04-Sep-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NU-RANIT TAB 150MG used for?
Treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, NSAID-induced lesions, and prophylaxis of GI hemorrhage.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00865737 |
|---|---|
| Brand name | NU-RANIT TAB 150MG |
| Generic / active ingredient | RANITIDINE (RANITIDINE HYDROCHLORIDE) : 150 MG |
| Manufacturer | NU-PHARM INC |
| Strength | 150 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BA02 RANITIDINE |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 04-Sep-2012 |
How is it administered?
Duodenal/gastric ulcer: 300 mg daily at bedtime or 150 mg twice daily. Reflux esophagitis: 150 mg twice daily or 300 mg at bedtime. Maintenance: 150 mg at bedtime. Doses adjusted for specific conditions.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C - 30°C (59°F - 86°F). Protect from light.
How is it supplied?
150 mg: Bottles of 60, 100, 500; unit dose packages of 60, 100. 300 mg: Bottles of 30, 100, 500; unit dose packages of 30, 100.
Contraindications
Contraindicated for patients known to have hypersensitivity to ranitidine.
Warnings and precautions
May mask symptoms of gastric carcinoma; avoid in patients with history of acute porphyria; increased risk of community acquired pneumonia in certain populations.
What can be used instead?
Other Canadian products sharing ATC code A02BA02 RANITIDINE. 5 of 96 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAR-RANITIDINE | 150 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02443708 |
| MAR-RANITIDINE | 300 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02443716 |
| MAXIMUM STRENGTH ACID REDUCER WITHOUT PRESCRIPTION | 150 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02293471 |
| MINT-RANITIDINE | 150 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02526379 |
| MINT-RANITIDINE | 300 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02526387 |
| ACID REDUCER | 150 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | APPROVED | DIN 02291282 |
| ACID REDUCER | 150 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02400103 |
| ACID REDUCER | 150 MG | TABLET | APOTEX INC | DORMANT | DIN 02296160 |
| ACID REDUCER | 75 MG | TABLET | WESTCAN PHARMACEUTICALS LTD. | CANCELLED PRE MARKET | DIN 02240348 |
| ACID REDUCER | 75 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02237829 |
Who else supplies RANITIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RANITIDINE appears in 4061 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.